Post by highskier on Feb 9, 2021 17:17:41 GMT
Sorrento Announces Subsidiary Company - ADNAB, Inc. - to Develop and Commercialize ADNAB™ Platform Products for Hematological Malignancies and Solid Tumors Based on an Exclusive Technology License From the Mayo Clinic
Sorrento Therapeutics, Inc.
Mon, February 8, 2021, 3:21 PM·7 min read
The ADNAB™ platform was developed and exclusively licensed to Sorrento by the Mayo Clinic
Clinical studies utilizing the ADNAB™ platform are ongoing at the Mayo Clinic; and are evaluating multiple platform-generated products in advanced-stage: endometrial cancer, ovarian cancer, angiosarcoma, and B-Cell lymphomas
Study LS1681 is a Mayo Investigator-Initiated-Trial (IIT) for relapsed or refractory B-cell lymphomas; and is evaluating rituximab-ADNAB™ (nab-paclitaxel nanoparticles non-covalently coated with rituximab)1
Study MC1371 is a Mayo Investigator-Initiated-Trial (IIT) for various solid tumors; and has completed a dose escalation phase2. To date, 9 endometrial and ovarian cancer patients, that had failed at least one prior regimen containing bevacizumab, were treated with bevacizumab-ADNAB™ (nab-paclitaxel nanoparticles non-covalently coated with bevacizumab).3
SAN DIEGO, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced the formation of ADNAB, Inc., a subsidiary Company, that will develop and commercialize a Mayo Clinic-developed technology platform for the manufacture of antibody-drug conjugates (ADC), each called an ADNAB™.
Sorrento Therapeutics, Inc.
Mon, February 8, 2021, 3:21 PM·7 min read
The ADNAB™ platform was developed and exclusively licensed to Sorrento by the Mayo Clinic
Clinical studies utilizing the ADNAB™ platform are ongoing at the Mayo Clinic; and are evaluating multiple platform-generated products in advanced-stage: endometrial cancer, ovarian cancer, angiosarcoma, and B-Cell lymphomas
Study LS1681 is a Mayo Investigator-Initiated-Trial (IIT) for relapsed or refractory B-cell lymphomas; and is evaluating rituximab-ADNAB™ (nab-paclitaxel nanoparticles non-covalently coated with rituximab)1
Study MC1371 is a Mayo Investigator-Initiated-Trial (IIT) for various solid tumors; and has completed a dose escalation phase2. To date, 9 endometrial and ovarian cancer patients, that had failed at least one prior regimen containing bevacizumab, were treated with bevacizumab-ADNAB™ (nab-paclitaxel nanoparticles non-covalently coated with bevacizumab).3
SAN DIEGO, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced the formation of ADNAB, Inc., a subsidiary Company, that will develop and commercialize a Mayo Clinic-developed technology platform for the manufacture of antibody-drug conjugates (ADC), each called an ADNAB™.
An ADNAB™ is an immune complex of nanoparticle albumin-bound drug products e.g., nab-paclitaxel, which are non-covalently conjugated with tumor-targeting monoclonal antibodies (mAb’s). The ADNAB™ platform was developed by Svetomir Markovic, M.D., Ph.D., and his research team at Mayo Clinic. To date, Dr. Markovic’s team have successfully formed nine (9) potential ADNAB™ candidates, including two (2) that are currently enrolling in an FDA supervised, investigator-initiated human trial.
Utilizing Sorrento’s G-MAB™ library of fully humanized monoclonal antibodies, the ADNAB™ platform will generate a broad portfolio of product candidates targeting liquid and solid tumors. “We believe this platform has broad potential.” said Henry Ji, Ph.D., Chairman and CEO of the newly formed ADNAB, Inc. “Our Vision, is to extend the reach of this platform to therapeutic areas beyond oncology; we have already begun work on an ADNAB™ for auto-immune diseases.”
Mayo Clinic physician Tom Habermann, M.D., serves as the Principal Investigator for Study LS1681, which is evaluating a rituximab-ADNAB™ in relapsed/refractory B-cell lymphomas. Relapsed-Refractory Diffuse Large B Cell Lymphoma (RR DLBCL), which accounts for approximately one-third of patients with DLBCL, remains a major cause of morbidity and mortality.
“I think this technology has the potential to be impactful” said Bradley J. Monk, M.D., Professor of Gynecologic Oncology at the University of Arizona College of Medicine. “I’m especially excited by the flexibility of this platform and I’m anxious to see what we might be able to do with a product that targets CA-125,” added Dr. Monk.
“The Mayo team has spent years fine-tuning this technology and now we have a collaborator that can provide the resources necessary to accelerate and scale this program,” said Svetomir Markovic, M.D., Ph.D., who discovered and developed the ADNAB™ platform technology.
“The published clinical studies testing this platform technology are encouraging and we are looking forward to working with the Mayo team on both the ongoing and future clinical studies. Unquestionably, Sorrento and Mayo share the common goal of utilizing this technology to develop multiple therapies for the possible benefit of cancer patients,” noted Ji.
ADNAB, Inc. plans to file multiple INDs this year; and to request Breakthrough Therapy designation from the FDA in both ovarian and endometrial cancers.
Mayo Clinic physician Tom Habermann, M.D., serves as the Principal Investigator for Study LS1681, which is evaluating a rituximab-ADNAB™ in relapsed/refractory B-cell lymphomas. Relapsed-Refractory Diffuse Large B Cell Lymphoma (RR DLBCL), which accounts for approximately one-third of patients with DLBCL, remains a major cause of morbidity and mortality.
“I think this technology has the potential to be impactful” said Bradley J. Monk, M.D., Professor of Gynecologic Oncology at the University of Arizona College of Medicine. “I’m especially excited by the flexibility of this platform and I’m anxious to see what we might be able to do with a product that targets CA-125,” added Dr. Monk.
“The Mayo team has spent years fine-tuning this technology and now we have a collaborator that can provide the resources necessary to accelerate and scale this program,” said Svetomir Markovic, M.D., Ph.D., who discovered and developed the ADNAB™ platform technology.
“The published clinical studies testing this platform technology are encouraging and we are looking forward to working with the Mayo team on both the ongoing and future clinical studies. Unquestionably, Sorrento and Mayo share the common goal of utilizing this technology to develop multiple therapies for the possible benefit of cancer patients,” noted Ji.
ADNAB, Inc. plans to file multiple INDs this year; and to request Breakthrough Therapy designation from the FDA in both ovarian and endometrial cancers.